Brief: Oncolytics Biotech Funds Pelareorep's Ongoing Clinical Development with a Share Purchase Agreement in Partnership with Alumni Capital
10/04/2025 23:23
April 10 (Reuters) - Oncolytics Biotech Inc ONC.TO: ONCOLYTICS BIOTECH® FUNDS PELAREOREP'S ONGOING CLINICAL DEVELOPMENT WITH A SHARE PURCHASE AGREEMENT IN PARTNERSHIP WITH ALUMNI CAPITAL ONCOLYTICS BIOTECH INC - UNDER AGREEMENT, CAN SELL UP TO $20 MILLION IN STOCK TO ALUMNI Source text: ID:nCNW4nF63a Further company coverage: ONC.TO ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Oncolytics Biotech
See all newsBrief: Oncolytics Biotech Files For Mixed Shelf Offering Of Up To $150 Million
Brief: Oncolytics Biotech® Announces Voluntary Delisting From The Toronto Stock Exchange
Advisory: Alert on global oncology breakthroughs tagged to multiple pharma firms withdrawn
Brief: Oncolytics Biotech® Appoints Former Ambrx Executive As Chief Business Officer
Brief: Oncolytics Biotech Appoints Former Ambrx Executive As Chief Business Officer